糖皮质激素在新型冠状病毒肺炎重型患者治疗中的临床研究

doi:10.3969/j.issn.1006-7795.2020.03.005

首都医科大学学报 ›› 2020, Vol. 41 ›› Issue (3): 345-349.doi: 10.3969/j.issn.1006-7795.2020.03.005

• 新型冠状病毒肺炎的诊断、治疗及预后 • 上一篇下一篇

糖皮质激素在新型冠状病毒肺炎重型患者治疗中的临床研究

李新刚^1,2, 徐艳利¹, 王琳¹, 周洋¹, 杨莉¹, 谭大伟¹, 陈志海¹, 宋蕊¹

1. 首都医科大学附属北京地坛医院感染性疾病诊疗中心, 北京 100015;
2. 首都医科大学附属北京地坛医院内分泌科, 北京 100015

收稿日期:2020-03-20 出版日期:2020-06-21 发布日期:2020-06-17
通讯作者: 宋蕊 E-mail:13126595640@126.com
基金资助:
北京市中医药科技发展资金资助项目（YJ2020-01）。

Clinical research of glucocorticoid treatment in severe cases of COVID-19

Li Xingang^1,2, Xu Yanli¹, Wang Lin¹, Zhou Yang¹, Yang Li¹, Tan Dawei¹, Chen Zhihai¹, Song Rui¹

1. Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China;
2. Department of Endocrinology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

Received:2020-03-20 Online:2020-06-21 Published:2020-06-17
Supported by:
This study was supported by Beijing Traditional Chinese Medicine Technology Development Fund(YJ2020-01).

摘要/Abstract

摘要： 目的探讨糖皮质激素在新型冠状病毒肺炎（以下简称新冠肺炎，COVID-19）重型患者治疗中的作用。方法选取2020年1月20日至2月20日在首都医科大学附属北京地坛医院感染性疾病诊疗中心住院应用糖皮质激素治疗的新冠肺炎重型患者3例，同时选取同期住院应用常规治疗的3例新冠肺炎重型患者作为对照。结果与常规治疗组相比，糖皮质激素治疗组患者体温恢复正常的时间缩短[（2.7±1.2）d vs（6.3±0.6）d，P<0.05]、氧合指数恢复（大于300 mm Hg，1 mmHg=0.133 kPa）快[（4.6±2.1）d vs（10.6±3.1）d，P<0.05]、肺部影像学好转的时间缩短[（4.3±1.5）d vs（7.6±1.2）d，P<0.05]。吸氧时间缩短[（12.1±0.8）d vs（21.7±5.7）d，P<0.05]，临床症状缓解时间缩短[（2.3±0.5）d vs（7.3±0.6）d，P<0.05]。结论糖皮质激素对新冠肺炎重型患者临床症状缓解、氧合改善、肺部病变吸收有促进作用，在治疗过程中可以尝试早期小剂量短疗程使用。

关键词: 新型冠状病毒肺炎, 重型, 糖皮质激素

Abstract: Objective To evaluate the effect of glucocorticoid (GC) on severe cases of COVID-19. Methods There were 6 severe cases of diagnosed COVID-19 patients enrolled in Beijing Ditan Hospital during January 20th and February 20th in 2020.According to treatments,these patients were divided into two groups:GC group and control group. Results Compared with control group, the recovery of temperature[(2.7±1.2) d vs (6.3±0.6) d, P<0.05],oxygenation index (more than 300 mmHg,1 mmHg=0.133 kPa)[(4.6±2.1) d vs (10.6±3.1) d, P<0.05], pulmonary inflammation[(4.3±1.5) d vs (7.6±1.2) d, P<0.05] and the clinical symptoms improvement[(2.3±0.5) d vs (7.3±0.6) d, P<0.05] were earlier in GC group, and the time of oxygen inhalation was shortened[(12.1±0.8) d vs (21.7±5.7) d, P<0.05]. Conclusion Earlier use of glucocorticoid with small doses could alleviate clinical symptoms, improve their clinical courses, and promote the absorbance of infiltration in their lungs manifested in chest computed tomography(CT)for the severe cases of COVID-19.

Key words: COVID-19, severe case, glucocorticoid

中图分类号:

R563.1

李新刚, 徐艳利, 王琳, 周洋, 杨莉, 谭大伟, 陈志海, 宋蕊. 糖皮质激素在新型冠状病毒肺炎重型患者治疗中的临床研究[J]. 首都医科大学学报, 2020, 41(3): 345-349.

Li Xingang, Xu Yanli, Wang Lin, Zhou Yang, Yang Li, Tan Dawei, Chen Zhihai, Song Rui. Clinical research of glucocorticoid treatment in severe cases of COVID-19[J]. Journal of Capital Medical University, 2020, 41(3): 345-349.

参考文献

[1] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020,395(10223):497-506.
[2] Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding[J].Lancet,2020,395(10224):565-574.
[3] Ahmed A E. The predictors of 3- and 30-day mortality in 660 MERS-CoV patients[J]. BMC Infect Dis,2017,17(1):615.
[4] World Health Organization. Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected:Interim Guidance[EB/OL].(2020-01-12)[2020-03-19]. https://apps.who.int/iris/handle/10665/330893.
[5] 国家卫生健康委员会办公厅,国家中医药管理局办公室.新型冠状病毒肺炎诊疗方案(试行第六版)[EB/OL].(2020-02-19)[2020-03-18].http://www.nhc.gov.cn/xcs/zhengcwj/202002/8334a8326dd94d329df351d7da8aefc2.Shtml
[6] 国家卫生健康委员会办公厅,国家中医药管理局办公室.新型冠状病毒肺炎重型、危重型病例诊疗方案(试行第二版)[EB/OL].(2020-02-14)[2020-3-18].http://www.nhc.gov.cn/yzygj/s7653p/202004/c083f2b0e7eb4036a59be419374ea89a.shtml.
[7] 李威,柳德兵.甲泼尼龙琥珀酸钠治疗新型冠状病毒肺炎的有效窗口期[J/OL].武汉大学学报(医学版).(2020-03-23)[2020-03-24].https://doi.org/10.14188/j.1671-8852.2020.0168.
[8] 陈倩,裴茂华,王瑶,等.糖皮质激素在新型冠状病毒肺炎中应用的利与弊[J/OL].武汉大学学报(医学版):(2020-03-09)[2020-03-24].https://doi.org/10.14188/j.1671-8852.2020.0136.
[9] 连玉菲,刘洪涛,高海祥,等.奥司他韦联合痰热清注射液治疗小儿病毒性肺炎的效果及安全性[J].解放军医药杂志,2018,30(12):48-52.
[10] Stern A, Skalsky K, Avni T,et al. Corticosteroids for pneumonia[J]. Cochrane Database Syst Rev, 2017, 12(12):CD007720.
[11] Russell C D, Millar J E, Baillie J K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury[J]. Lancet, 2020,395(10223):473-475.
[12] Wong C K, Lam C W, Wu A K, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome[J].Clin Exp Immunol, 2004,136(1):95-103.
[13] 董红建,谭捷.糖皮质激素联合参芪扶正注射液辅治重症社区获得性肺炎致ARDS患者效果观察及对血清炎性因子、血气指标影响[J].临床误诊误治,2019,32(11):25-29.
[14] Falsey A R, Walsh E E. Novel coronavirus and severe acute respiratory syndrome[J]. Lancet, 2003, 361(9366):1312-1313.
[15] Wan S X, Yi Q J, Fan S B, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)[J/OL]. Medrxiv.(2020-2-12)[2020-03-20].https://www.medrxiv.org/content/10.1101/2020.02.10.20021832v1.
[16] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020,8(4):420-422.
[17] Auyeung T W, Lee J S, Lai W K, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes:a retrospective cohort study[J]. J Infect,2005, 51(2):98-102.
[18] Chen S, Wu J J, Li Z M, et al. Clinical features of 109 cases of novel coronavirus pneumonia[J/OL]. Chin J Infect Dis.(2020-02-27)[2020-3-19].http://rs.yiigle.com/yufabiao/1186991.htm.
[19] Wu C, Chen X, Cai Y, et al. Risk factors associated with qcute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China[J]. JAMA Intern Med.(2020-03-13)[2020-03-19].https://jamanetwork.com/journals/jamain ternalmedicine/fullarticle/2763184.doi:10.1001/jamainternmed.2020.0994.
[20] Zhou W, Liu Y, Tian D, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia[J]. Signal Transduct Target Ther, 2020,5(1):18.

糖皮质激素在新型冠状病毒肺炎重型患者治疗中的临床研究

Clinical research of glucocorticoid treatment in severe cases of COVID-19

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王向东, 姜敏, 王鑫, 巩永凤. 糖皮质激素受体在缺血再灌注肾损伤中的作用[J]. 首都医科大学学报, 2022, 43(2): 260-268.
[2]	赵珂, 马建民, 肖飞, 刘向祎. IL-6、TNF-α、GR-α、GR-β mRNA与常见眼眶疾病患者对糖皮质激素敏感性的关系[J]. 首都医科大学学报, 2021, 42(5): 747-753.
[3]	刘珊珊, 陈旭, 李亚琼, 袁晓菲, 于红晔, 房萌. 新型冠状病毒肺炎疫情期间北京市青少年抑郁焦虑情况调查及影响因素[J]. 首都医科大学学报, 2021, 42(3): 412-417.
[4]	陈剑明, 陈腾飞, 连博, 陈奕杉, 徐霄龙, 刘清泉. 新型冠状病毒肺炎中医证候和证候要素分布特点的文献分析[J]. 首都医科大学学报, 2020, 41(6): 901-907.
[5]	尹星琪, 于彩果, 柯静, 赵冬, 于可. 2型糖尿病患者新型冠状病毒肺炎流行期间心理状态及行为调查[J]. 首都医科大学学报, 2020, 41(6): 970-977.
[6]	姚春勇, 李杨帆, 贾原菊. 66例新型冠状病毒肺炎患者临床特点及胸部电子计算机断层扫描影像表现分析[J]. 首都医科大学学报, 2020, 41(6): 997-1001.
[7]	慕萌, 张俊敏, 陈瑞芳, 孙超渊. 医学类科技期刊应对新型冠状病毒肺炎(COVID-19)的策略分析——以《首都医科大学学报》为例[J]. 首都医科大学学报, 2020, 41(6): 1033-1036.
[8]	安彦虹, 戎冬冬, 单艺, 武春雪, 高艳, 卢洁. 新型冠状病毒肺炎疑似与确诊患者的胸部X线表现比较[J]. 首都医科大学学报, 2020, 41(4): 608-612.
[9]	胡琪, 钟正, 刘激扬, 汤渝玲, 周志国, 刘萍, 阎昱升, 李波. 57例新型冠状病毒肺炎治愈患者胸部电子计算机断层扫描特征报告[J]. 首都医科大学学报, 2020, 41(4): 627-630.
[10]	杨毅, 鲁旭然, 刘楠, 侯晓彤, 孙立忠, 吴龙, 潘友民, 王守凤, 赵欣艳. 新型冠状病毒肺炎对心血管系统影响[J]. 首都医科大学学报, 2020, 41(4): 657-663.
[11]	刘景院, 郭贺冰, 李昂. 危重型新型冠状病毒肺炎的诊疗进展[J]. 首都医科大学学报, 2020, 41(3): 321-327.
[12]	刘景院, 郭贺冰, 李昂. 新型冠状病毒肺炎诊疗的若干思考[J]. 首都医科大学学报, 2020, 41(3): 328-335.
[13]	吕志彬, 关春爽, 闫铄, 陈七一, 李晶晶, 张羽君, 陈步东, 谢汝明. 人工智能在CT预测新型冠状病毒肺炎转归中的价值[J]. 首都医科大学学报, 2020, 41(3): 340-344.
[14]	金荣华. 新型冠状病毒肺炎[J]. 首都医科大学学报, 2020, 41(2): 149-154.
[15]	李丽, 杨华升, 勾春燕, 汪晓军, 罗晓岚, 张佳莹, 李红艳, 李侗曾, 梁连春, 李秀惠. 46例新型冠状病毒肺炎中医临床特征分析[J]. 首都医科大学学报, 2020, 41(2): 155-160.